Clinical Trials Logo

Clinical Trial Summary

This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05454241
Study type Interventional
Source Institute of Hematology & Blood Diseases Hospital
Contact Ying Wang, doctor
Phone +86-22-23909278
Email wangying1@ihcams.ac.cn
Status Recruiting
Phase Phase 2
Start date September 7, 2022
Completion date September 7, 2025

See also
  Status Clinical Trial Phase
Terminated NCT03248479 - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Phase 1
Recruiting NCT06041815 - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting NCT05005442 - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) Phase 2
Recruiting NCT02300571 - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant N/A
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Completed NCT01162096 - Reduced Intensity Haploidentical Transplant for Hematological Malignancies Phase 1/Phase 2
Completed NCT00379587 - Rituximab for Prevention of Chronic GVHD Phase 1/Phase 2
Terminated NCT00506948 - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) Phase 2
Active, not recruiting NCT04557098 - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Phase 2
Recruiting NCT04283097 - Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Phase 1
Completed NCT03067155 - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. Phase 2
Completed NCT01725555 - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors Phase 1
Completed NCT00438178 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Phase 1
Completed NCT03711604 - Compassionate Use Study of Tenalisib (RP6530) Phase 1/Phase 2
Withdrawn NCT01168882 - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies Phase 1
Completed NCT01246206 - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT Phase 2
Completed NCT01172132 - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" N/A
Completed NCT00506402 - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT00163644 - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT N/A
Completed NCT01063647 - Dose-range Finding Treosulfan-based Conditioning Phase 1/Phase 2